ClinicalTrials.gg
CompletedNCT02565914Updated Sep 28, 2023Results posted

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

A Phase 3 interventional study of TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 159 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,131
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
Largest of 43
1,131 · median 100
Started
2015
with 4 others
Phase 3
25 of 43
none open now
Registered
9th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one has the largest enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 9th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, open-label, 3-part rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in studies VX13-661-103 (Study 103, NCT02070744), VX14-661-106 (Study 106, NCT02347657), VX14-661-107 (Study 107, NCT02516410), VX14-661-108 (Study 108, NCT02392234), VX14-661-109 (Study 109, NCT02412111), VX14-661-111 (Study 111, NCT02508207), VX15-661-112 (NCT02730208), and VX16-661-114 (NCT03150719). The study is designed to evaluate the safety and efficacy of long-term treatment of VX-661 in combination with ivacaftor.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • Participants entering the Treatment Cohort must meet all of the following criteria:
  • Elect to enroll in the Treatment Cohort
  • Completed study drug Treatment Period in a parent study (NCT02070744, NCT02347657, NCT02516410, NCT02392234, NCT02412111) or study drug treatment and the Safety Follow up Visit for participants from NCT02508207.
  • Willing to remain on a stable CF regimen through the Safety Follow-up Visit.
  • Participants re-enrolling in the Part A Treatment Cohort must meet all of the following criteria:

    • Previously received at least 4 weeks of study drug before discontinuing in Part A of Study NCT02565914 to participate in another qualified Vertex study.
    • Completed the last required visit of another qualified Vertex study before or during the Returning Visit in Part A Study NCT02565914.
  • Participants entering the Part A Observational Cohort must meet the following criteria:

    • \<18 years of age (age on the date of /assent in the parent study)
    • Completed study drug Treatment Period in a parent study or study drug treatment and the Safety Follow up Visit for subjects from NCT02508207, but do not elect to enroll in the NCT02565914 Treatment Cohort; or
    • Received at least 4 weeks of study drug treatment and completed visits up to the last scheduled visit of the Treatment Period of a parent study (and the Safety Follow up Visit for participants from NCT02508207), but do not meet eligibility criteria for enrollment into the Treatment Cohort

Part B:

Participants who meet all of the following inclusion criteria will be eligible for Part B.

  • Did not withdraw consent from the parent study or Part A of Study NCT02565914.
  • Completed study drug treatment during the Treatment Period in Part A of - Willing to remain on a stable CF medication (and supplement) regimen through the 96 week visit of Study NCT02565914.

Participants re enrolling in Part B must meet all of the following criteria:

  • Previously received at least 4 weeks of study drug before discontinuing Study NCT02565914 to participate in another qualified Vertex study, which is defined as a Vertex study of CFTR modulators that allows participation of participants in Study NCT02565914.
  • Completed the last required visit of another qualified Vertex study before or during the Returning Visit in Part B.
  • Willing to remain on a stable CF medication (and supplement) regimen through the 96 week visit in Part B.

Part C:

  • Participants who meet all of the following inclusion criteria will be eligible for Part C.
  • Did not withdraw consent from Part B of Study NCT02565914.
  • Completed study drug treatment during Part B of NCT02565914.
  • Willing to remain on a stable CF medication (and supplement) regimen through the 96 week visit of Part C.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject.
  • Pregnant and nursing females.
  • Sexually active subjects of who are not willing to follow the requirements.
  • History of drug intolerance in the parent study that would pose an additional risk to the subject.
  • Participation in an drug trial (including studies investigating VX-661/ivacaftor or lumacaftor/ivacaftor) other than the parent studies of NCT02565914 or other eligible Vertex studies investigating VX-661 in combination with ivacaftor, or use of a commercially available CFTR modulator.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,131 participants (actual)

Study arms

  • Experimental
    TEZ/IVA

    Part A: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 103,106,107,108,109 and 111 were administered TEZ 100 milligram (mg)/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks. Part B: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108,109,112 and 114 were administered TEZ 100 mg/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks. Part C: Participants who received TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108, and 114 were administered TEZ 100 mg/IVA 150 mg fixed dose tablet in the morning and IVA 150 mg mono tablet in the evening for 192 weeks.

    Drug: TEZ/IVA · Drug: IVA

Interventions

  • DrugTEZ/IVA

    Drug pages: Tezacaftor · Ivacaftor

    Fixed dose tablet for oral administration.

    Also known as: VX-661/VX-770, tezacaftor/ivacaftor

  • DrugIVA

    Tablet for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 100

  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs

    Time frame: Day 1 up to Week 100

  3. Part C: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 196

Secondary outcomes

  1. Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  2. Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  3. Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  4. Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  5. Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  6. Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  7. Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  8. Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  9. Part A: Number of Pulmonary Exacerbation (PEx) Events for 106/110 PEx Analysis Set

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline up to Study 110 Week 96

  10. Part A: Number of Pulmonary Exacerbation (PEx) Events for 108/110 PEx Analysis Set

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline up to Week 96

  11. Part A: Absolute Change in Body Mass Index (BMI) for 106/110 Efficacy Set

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  12. Part A: Absolute Change in Body Mass Index (BMI) for 108/110 Efficacy Set

    BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  13. Part A: Absolute Change in Body Mass Index (BMI) for 103/110 Efficacy Set

    BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  14. Part A: Absolute Change in Body Mass Index (BMI) for Study 111/110 Efficacy Set

    BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  15. Part A: Absolute Change in BMI Z-score for 106/110 Efficacy Set

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  16. Part A: Absolute Change in BMI Z-score for 108/110 Efficacy Set

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  17. Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 106/110 Efficacy Set

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  18. Part A: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 108/110 Efficacy Set

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  19. Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/110 Efficacy Set

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  20. Part A: Absolute Change in Body Weight for Study 106/110 Efficacy Set

    Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  21. Part A: Absolute Change in Body Weight for 108/110 Efficacy Set

    Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  22. Part A: Absolute Change in Body Weight for 103/110 Efficacy Set

    Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  23. Part A: Absolute Change in Body Weight for 111/110 Efficacy Set

    Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  24. Part A: Absolute Change in Body Weight Z-score for 106/110 Efficacy Set

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  25. Part A: Absolute Change in Body Weight Z-score for 108/110 Efficacy Set

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  26. Part A: Absolute Change in Height Z-score for 106/110 Efficacy Set

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

    Time frame: From Baseline at Study 110 Week 96

  27. Part A: Absolute Change in Height Z-score for 108/110 Efficacy Set

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

    Time frame: From Baseline at Study 110 Week 96

  28. Part A: Time-to-first Pulmonary Exacerbation (PEx) for 106/110 PEx Analysis Set

    Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan.

    Time frame: 96 weeks

  29. Part A: Time-to-first Pulmonary Exacerbation (PEx) for 108/110 PEx Analysis Set

    Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan.

    Time frame: 96 weeks

  30. Part A: Plasma Concentrations of TEZ, TEZ Metabolite (M1-TEZ), Ivacaftor (IVA) and Ivacaftor Metabolite (M1-IVA)

    Time frame: Week 24

  31. Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline at Study 110 Week 96

  32. Part B: Absolute Change in Body Mass Index (BMI)

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

    Time frame: From Baseline at Week 96

  33. Part B: Absolute Change in BMI Z-score

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Baseline at Week 96

  34. Part B: Number of Pulmonary Exacerbation (PEx) Events

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Baseline up to Week 96

07

Results

Posted Jun 16, 2020

Participant flow

This study consisted of 3 parts: Parts A, B, and C.

Part A (Up to 96 Weeks)
Participant flow — Part A (Up to 96 Weeks)
MilestoneTEZ/IVA
Started1044
Safety set1042
Completed951
Not completed93
Withdrew: Adverse event17
Withdrew: Withdrawal of consent (not due to ae)25
Withdrew: Lost to follow-up12
Withdrew: Death (not treatment emergent)1
Withdrew: Other noncompliance6
Withdrew: Physician decision6
Withdrew: Parent study termination by sponsor1
Withdrew: Commercial drug available5
Withdrew: Other18
Withdrew: Enrolled, but did not receive study drug2
Part B (Up to 96 Weeks)
Participant flow — Part B (Up to 96 Weeks)
MilestoneTEZ/IVA
Started464
Safety set463
Completed228
Not completed236
Withdrew: Physician decision1
Withdrew: Other1
Withdrew: Enrolled, but did not receive study drug1
Withdrew: Adverse event4
Withdrew: Sponsor decision2
Withdrew: Rolled over into another study25
Withdrew: Withdrawal of consent (not due to ae)6
Withdrew: Commercial drug is available for participant196
Part C (Up to 192 Weeks)
Participant flow — Part C (Up to 192 Weeks)
MilestoneTEZ/IVA
Started204
Safety set204
Completed7
Not completed197
Withdrew: Physician decision5
Withdrew: Adverse event1
Withdrew: Other non-compliance2
Withdrew: Rolled over into another study11
Withdrew: Withdrawal of consent (not due to ae)4
Withdrew: Commercial drug is available for participant174

Outcome measures

PrimaryPart A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 100
Reported as:
Count of participants · Participants
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: TEZ/IVA
Participants with TEAEs995
Participants with SAEs351
PrimaryPart B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs
Time frame:
Day 1 up to Week 100
Reported as:
Count of participants · Participants
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs
ParticipantsPart B: TEZ/IVA
Participants with TEAEs427
Participants with SAEs136
PrimaryPart C: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 196
Reported as:
Count of participants · Participants
Part C: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart C: TEZ/IVA
Participants with TEAEs168
Participants with SAEs44
SecondaryPart A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · percentage points
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set
percentage pointsPart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 962.1 (0.8 to 3.3)
TEZ/IVA-TEZ/IVA: Change at Week 962.0 (0.7 to 3.2)
SecondaryPart A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · percentage points
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set
percentage pointsPart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 964.1 (2.2 to 6.0)
IVA-TEZ/IVA: Change at Week 966.7 (4.7 to 8.7)
TEZ/IVA-TEZ/IVA: Change at Week 967.5 (5.6 to 9.4)
SecondaryPart A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · percentage points
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set
percentage pointsPart A: TEZ/IVA
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set2.7 ± 10.0
SecondaryPart A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · percentage points
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set
percentage pointsPart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 964.1 ± 10.2
TEZ/IVA-TEZ/IVA: Change at Week 962.6 ± 6.6
SecondaryPart A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · percent change
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set
percent changePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 964.3 (2.1 to 6.5)
TEZ/IVA-TEZ/IVA: Change at Week 964.2 (2.0 to 6.4)
SecondaryPart A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · percent change
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set
percent changePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 967.9 (4.7 to 11.1)
IVA-TEZ/IVA: Change at Week 9611.6 (8.2 to 15.0)
TEZ/IVA-TEZ/IVA: Change at Week 9613.0 (9.7 to 16.2)
SecondaryPart A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · percent change
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set
percent changePart A: TEZ/IVA
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set6.4 ± 21.1
SecondaryPart A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · percent change
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set
percent changePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 966.1 ± 14.4
TEZ/IVA-TEZ/IVA: Change at Week 965.2 ± 11.5
SecondaryPart A: Number of Pulmonary Exacerbation (PEx) Events for 106/110 PEx Analysis Set

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline up to Study 110 Week 96
Reported as:
Number · PEx events
Part A: Number of Pulmonary Exacerbation (PEx) Events for 106/110 PEx Analysis Set
PEx eventsPart A: TEZ/IVA
Placebo-TEZ/IVA306
TEZ/IVA-TEZ/IVA423
SecondaryPart A: Number of Pulmonary Exacerbation (PEx) Events for 108/110 PEx Analysis Set

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline up to Week 96
Reported as:
Number · PEx events
Part A: Number of Pulmonary Exacerbation (PEx) Events for 108/110 PEx Analysis Set
PEx eventsPart A: TEZ/IVA
Placebo-TEZ/IVA89
IVA-TEZ/IVA51
TEZ/IVA-TEZ/IVA46
SecondaryPart A: Absolute Change in Body Mass Index (BMI) for 106/110 Efficacy Set

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · kg/m^2
Part A: Absolute Change in Body Mass Index (BMI) for 106/110 Efficacy Set
kg/m^2Part A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 960.47 (0.30 to 0.65)
TEZ/IVA-TEZ/IVA: Change at Week 960.38 (0.20 to 0.55)
SecondaryPart A: Absolute Change in Body Mass Index (BMI) for 108/110 Efficacy Set

BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · kg/m^2
Part A: Absolute Change in Body Mass Index (BMI) for 108/110 Efficacy Set
kg/m^2Part A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 961.07 (0.59 to 1.55)
IVA-TEZ/IVA: Change at Week 960.96 (0.45 to 1.47)
TEZ/IVA-TEZ/IVA: Change at Week 961.05 (0.56 to 1.55)
SecondaryPart A: Absolute Change in Body Mass Index (BMI) for 103/110 Efficacy Set

BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · kg/m^2
Part A: Absolute Change in Body Mass Index (BMI) for 103/110 Efficacy Set
kg/m^2Part A: TEZ/IVA
Part A: Absolute Change in Body Mass Index (BMI) for 103/110 Efficacy Set1.38 ± 1.73
SecondaryPart A: Absolute Change in Body Mass Index (BMI) for Study 111/110 Efficacy Set

BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · kg/m^2
Part A: Absolute Change in Body Mass Index (BMI) for Study 111/110 Efficacy Set
kg/m^2Part A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 961.59 ± 2.08
TEZ/IVA-TEZ/IVA: Change at Week 960.26 ± 0.88
SecondaryPart A: Absolute Change in BMI Z-score for 106/110 Efficacy Set

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · z-score
Part A: Absolute Change in BMI Z-score for 106/110 Efficacy Set
z-scorePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 960.10 (-0.04 to 0.25)
TEZ/IVA-TEZ/IVA: Change at Week 96-0.14 (-0.28 to 0.00)
SecondaryPart A: Absolute Change in BMI Z-score for 108/110 Efficacy Set

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · z-score
Part A: Absolute Change in BMI Z-score for 108/110 Efficacy Set
z-scorePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 960.11 (-0.32 to 0.54)
IVA-TEZ/IVA: Change at Week 960.07 (-0.52 to 0.65)
TEZ/IVA-TEZ/IVA: Change at Week 960.30 (-0.21 to 0.80)
SecondaryPart A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 106/110 Efficacy Set

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · units on a scale
Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 106/110 Efficacy Set
units on a scalePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 961.7 (-0.6 to 4.0)
TEZ/IVA-TEZ/IVA: Change at Week 963.0 (0.7 to 5.3)
SecondaryPart A: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 108/110 Efficacy Set

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · units on a scale
Part A: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 108/110 Efficacy Set
units on a scalePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 9610.3 (7.0 to 13.6)
IVA-TEZ/IVA: Change at Week 9611.2 (7.7 to 14.7)
TEZ/IVA-TEZ/IVA: Change at Week 9613.8 (10.3 to 17.2)
SecondaryPart A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/110 Efficacy Set

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · units on a scale
Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/110 Efficacy Set
units on a scalePart A: TEZ/IVA
Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/110 Efficacy Set8.6 ± 12.1
SecondaryPart A: Absolute Change in Body Weight for Study 106/110 Efficacy Set

Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · kg
Part A: Absolute Change in Body Weight for Study 106/110 Efficacy Set
kgPart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 962.0 (1.4 to 2.5)
TEZ/IVA-TEZ/IVA: Change at Week 962.1 (1.5 to 2.6)
SecondaryPart A: Absolute Change in Body Weight for 108/110 Efficacy Set

Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · kg
Part A: Absolute Change in Body Weight for 108/110 Efficacy Set
kgPart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 963.5 (1.9 to 5.1)
IVA-TEZ/IVA: Change at Week 963.5 (1.8 to 5.2)
TEZ/IVA-TEZ/IVA: Change at Week 963.6 (2.0 to 5.2)
SecondaryPart A: Absolute Change in Body Weight for 103/110 Efficacy Set

Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · kg
Part A: Absolute Change in Body Weight for 103/110 Efficacy Set
kgPart A: TEZ/IVA
Part A: Absolute Change in Body Weight for 103/110 Efficacy Set4.0 ± 5.0
SecondaryPart A: Absolute Change in Body Weight for 111/110 Efficacy Set

Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · kg
Part A: Absolute Change in Body Weight for 111/110 Efficacy Set
kgPart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 964.2 ± 5.7
TEZ/IVA-TEZ/IVA: Change at Week 960.6 ± 2.6
SecondaryPart A: Absolute Change in Body Weight Z-score for 106/110 Efficacy Set

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · z-score
Part A: Absolute Change in Body Weight Z-score for 106/110 Efficacy Set
z-scorePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 960.07 (-0.06 to 0.20)
TEZ/IVA-TEZ/IVA: Change at Week 96-0.06 (-0.19 to 0.07)
SecondaryPart A: Absolute Change in Body Weight Z-score for 108/110 Efficacy Set

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · z-score
Part A: Absolute Change in Body Weight Z-score for 108/110 Efficacy Set
z-scorePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 960.15 (-0.25 to 0.55)
IVA-TEZ/IVA: Change at Week 960.09 (-0.45 to 0.62)
TEZ/IVA-TEZ/IVA: Change at Week 960.43 (-0.04 to 0.90)
SecondaryPart A: Absolute Change in Height Z-score for 106/110 Efficacy Set

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · z-score
Part A: Absolute Change in Height Z-score for 106/110 Efficacy Set
z-scorePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 960.01 (-0.08 to 0.11)
TEZ/IVA-TEZ/IVA: Change at Week 960.13 (0.04 to 0.22)
SecondaryPart A: Absolute Change in Height Z-score for 108/110 Efficacy Set

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Least squares mean · z-score
Part A: Absolute Change in Height Z-score for 108/110 Efficacy Set
z-scorePart A: TEZ/IVA
Placebo-TEZ/IVA: Change at Week 96-0.04 (-0.23 to 0.15)
IVA-TEZ/IVA: Change at Week 960.20 (-0.05 to 0.45)
TEZ/IVA-TEZ/IVA: Change at Week 960.23 (0.00 to 0.46)
SecondaryPart A: Time-to-first Pulmonary Exacerbation (PEx) for 106/110 PEx Analysis Set

Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan.

Time frame:
96 weeks
Reported as:
Number · event-free probability
Part A: Time-to-first Pulmonary Exacerbation (PEx) for 106/110 PEx Analysis Set
event-free probabilityPart A: TEZ/IVA
Placebo-TEZ/IVA0.470 (0.402 to 0.535)
TEZ/IVA-TEZ/IVA0.438 (0.374 to 0.501)
SecondaryPart A: Time-to-first Pulmonary Exacerbation (PEx) for 108/110 PEx Analysis Set

Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan.

Time frame:
96 weeks
Reported as:
Number · event-free probability
Part A: Time-to-first Pulmonary Exacerbation (PEx) for 108/110 PEx Analysis Set
event-free probabilityPart A: TEZ/IVA
Placebo-TEZ/IVA0.497 (0.383 to 0.601)
IVA-TEZ/IVA0.493 (0.372 to 0.603)
TEZ/IVA-TEZ/IVA0.639 (0.519 to 0.737)
SecondaryPart A: Plasma Concentrations of TEZ, TEZ Metabolite (M1-TEZ), Ivacaftor (IVA) and Ivacaftor Metabolite (M1-IVA)
Time frame:
Week 24
Reported as:
Mean · nanogram/milliliter (ng/mL)
Part A: Plasma Concentrations of TEZ, TEZ Metabolite (M1-TEZ), Ivacaftor (IVA) and Ivacaftor Metabolite (M1-IVA)
nanogram/milliliter (ng/mL)Part A: TEZ/IVA
VX-6612070 ± 1390
M1-6614580 ± 2080
IVA892 ± 700
M1-IVA1740 ± 1070
SecondaryPart B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline at Study 110 Week 96
Reported as:
Mean · percentage points
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart B: TEZ/IVA
F/F Mutation1.7 ± 10.2
F/RF Mutation8.3 ± 8.6
SecondaryPart B: Absolute Change in Body Mass Index (BMI)

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

Time frame:
From Baseline at Week 96
Reported as:
Mean · kg/m^2
Part B: Absolute Change in Body Mass Index (BMI)
kg/m^2Part B: TEZ/IVA
F/F Mutation0.70 ± 1.45
F/RF Mutation1.84 ± 2.21
SecondaryPart B: Absolute Change in BMI Z-score

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Baseline at Week 96
Reported as:
Mean · z-score
Part B: Absolute Change in BMI Z-score
z-scorePart B: TEZ/IVA
F/F Mutation-0.03 ± 0.71
F/RF Mutation0.21 ± 0.46
SecondaryPart B: Number of Pulmonary Exacerbation (PEx) Events

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Baseline up to Week 96
Reported as:
Number · PEx events
Part B: Number of Pulmonary Exacerbation (PEx) Events
PEx eventsPart B: TEZ/IVA
F/F Mutation386
F/RF Mutation94

Adverse events

Collected over Day 1 Through Safety Follow-up Visit (up to Week 100 for Part A, up to Week 100 for Part B and up to Week 196 for Part C). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: TEZ/IVA1/1,042 (0.1%)351/1,042 (33.7%)938/1,042 (90%)
Part B: TEZ/IVA0/463 (0%)136/463 (29.4%)391/463 (84.4%)
Part C: TEZ/IVA0/204 (0%)44/204 (21.6%)149/204 (73%)
Most frequent serious events
Showing 10 of 192
Most frequent serious events
EventPart A: TEZ/IVAPart B: TEZ/IVAPart C: TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations243/1042103/46328/204
HaemoptysisRespiratory, thoracic and mediastinal disorders25/104210/4636/204
Drug hypersensitivityImmune system disorders2/10422/4633/204
Distal intestinal obstruction syndromeGastrointestinal disorders12/10423/4631/204
PneumoniaInfections and infestations7/10424/4631/204
ConstipationGastrointestinal disorders8/10423/4630/204
Abdominal painGastrointestinal disorders7/10420/4630/204
InfluenzaInfections and infestations7/10421/4630/204
Blood creatine phosphokinase increasedInvestigations7/10420/4630/204
Intestinal obstructionGastrointestinal disorders4/10423/4630/204
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPart A: TEZ/IVAPart B: TEZ/IVAPart C: TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations444/1042202/46387/204
CoughRespiratory, thoracic and mediastinal disorders374/1042112/46329/204
NasopharyngitisInfections and infestations227/104288/46313/204
Sputum increasedRespiratory, thoracic and mediastinal disorders223/104246/46313/204
HaemoptysisRespiratory, thoracic and mediastinal disorders167/104264/46325/204
HeadacheNervous system disorders146/104247/46320/204
Oropharyngeal painRespiratory, thoracic and mediastinal disorders136/104239/4639/204
PyrexiaGeneral disorders135/104240/46320/204
Upper respiratory tract infectionInfections and infestations135/104243/46312/204
DiarrhoeaGastrointestinal disorders105/104227/4635/204

Baseline characteristics

Baseline data is based on the parent study baseline, which is defined as the most recent non-missing measurements collected before the first dose of the study drug in the treatment period of parent studies. Baseline data is presented for all participants who signed informed consent and enrolled, or dosed, in Part A, Part B, or Part C, respectively in this study.

Age, Continuous
Age, Continuous(years)TEZ/IVA
Part A29.13 ± 12.00
Part B29.61 ± 11.89
Part C29.60 ± 11.68
Sex: Female, Male
Sex: Female, Male(Participants)TEZ/IVA
Part A — Female505
Part A — Male539
Part B — Female221
Part B — Male243
Part C — Female89
Part C — Male115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TEZ/IVA
Part A — Hispanic or Latino25
Part A — Not Hispanic or Latino1002
Part A — Not collected per local regulations17
Part B — Hispanic or Latino6
Part B — Not Hispanic or Latino437
Part B — Not collected per local regulations21
Part C — Hispanic or Latino5
Part C — Not Hispanic or Latino184
Part C — Not collected per local regulations15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TEZ/IVA
Part A — White1017
Part A — Black or African American7
Part A — Asian2
Part A — American Indian or Alaska Native1
Part A — Native Hawaiian or Other Pacific Islander0
Part A — Not collected per local regulations11
Part A — Other6
Part B — White447
Part B — Black or African American1
Part B — Asian2
Part B — American Indian or Alaska Native0
Part B — Native Hawaiian or Other Pacific Islander0
Part B — Not collected per local regulations13
Part B — Other1
Part C — White193
Part C — Black or African American0
Part C — Asian1
Part C — American Indian or Alaska Native0
Part C — Native Hawaiian or Other Pacific Islander0
Part C — Not collected per local regulations10
Part C — Other0
08

Study locations

159 sites
  • Birmingham, Alabama, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Oakland, California, United States
  • Palo Alto, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Gainesville, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Glenview, Illinois, United States
  • Niles, Illinois, United States
  • Peoria, Illinois, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Lexington, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Lebanon, New Hampshire, United States
  • Long Branch, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Buffalo, New York, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Syracuse, New York, United States
  • Chapel Hill, North Carolina, United States
  • Akron, Ohio, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • Knoxville, Tennessee, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Tyler, Texas, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Morgantown, West Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Chermside, Australia
  • Melbourne, Australia
  • South Brisbane, Australia
  • Westmead, Australia
  • Graz, Austria
  • Innsbruck, Austria
  • Salzburg, Austria
  • Brussels, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Vancouver, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Halifax, Canada
  • Montreal, Canada
  • Montréal, Canada
  • Québec, Canada
  • Copenhagen, Denmark
  • Benite Cedex, France
  • Bordeaux Cedex, France
  • Bron Cedex, France
  • Lille, France
  • Marseilles, France
  • Montpellier Cedex 5, France
  • Paris Cedex 14, France
  • Paris Cedex 15, France
  • Paris, France
  • Rennes Cedex, France
  • Roscoff Cedex, France
  • Rouen Cedex, France
  • Berlin, Germany
  • Bochum, Germany

Showing the first 100 of 159 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Erratum In: Lancet Respir Med. 2021 Apr;9(4):e38. doi: 10.1016/S2213-2600(21)00122-3. PubMed 33581080 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in May 2019, 45 months.

Results were first posted in Jun 2020, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 45 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2015
First posted
Oct 1, 2015
StartActual
Aug 2015
Primary completionActual
May 2019
CompletionActual
Dec 5, 2022
Results first posted
Jun 16, 2020
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02565914
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Aug 2015
Primary completion
May 2019
Completion
Dec 5, 2022
Results posted
Jun 16, 2020
Last update
Sep 28, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion